[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-arteriosclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-arteriosclerosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,58,91,120,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100570032","effects-of-a-healthy-nordic-diet-on-atherosclerosis-in-patients-with-coronary-heart-disease-100570032",false,"NCT06701968","Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease","A Healthy Nordic Diet to Reduce the Progression of Atherosclerosis in Individuals with Coronary Heart Disease: a Secondary Prevention Trial","NORDHEART","Inclusion Criteria:\n\n* Men and women\n* Diagnosis with MI from 2 weeks after diagnosis and with maximum 6 months after diagnosis\n* Diagnosis with CCS (e.g. stable angina pectoris)\n* Ages 50 to 80 years\n* BMI 25-40.\n\nExclusion Criteria:\n\n* Severe heart failure (NYHA classes III, IV)\n* Alcohol intake \\>20g\u002Fday\n* Unwillingness to follow a new prescribed diet for 18 months\n* Other diseases implying a short estimated life expectancy (e.g. severe malignant or kidney or liver disease, as judged by consenting physician).","ALL","50 Years","80 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","Diet can play a key role in atherosclerosis and coronary heart disease (CHD), but little interventional data exists, and the mediators of possible anti-atherosclerotic effects of diet are unclear. The investigators will investigate if a healthy Nordic diet (HND) reduces plaque volume, coronary artery calcification (CAC), and plaque inflammation (FAI) in CHD, and examine if changes in gut microbiota may be linked to plaque progression over time. The investigators will also explore if the diet response can be predicted by the metabolic phenotype.\n\nIn total 150 CHD patients is randomized to a HND rich in unsaturated fat and fibre from plants, or to a \"usual care diet\" for 18 months. Plaque volume and composition is assessed by CT, and fecal microbiota composition is determined by deep metagenome shotgun sequencing. CHD and metabolic risk factors, liver fat, muscle fat and biomarkers of diet adherence (plasma fatty acids, whole-grain metabolites) are measured. Machine-learning is used to identify diet \"responders\" on plaque progression, based on the individual microbiome and metabolome.\n\nIf a HND reduces plaque progression, this would be novel information of clinical importance. Also, if the diet alters microbiota that are linked to plaque progression, this would be of high scientific interest. Finally, potential prediction of the diet-response would open up for more personalized treatment of atherosclerosis.",[28,29,30,31,32,33],"Coronary Disease","Coronary Arteriosclerosis","Myocardial Infarction","Chronic Coronary Syndrome","MASLD","Type 2 Diabetes",[35,36,37,38,39,40,41,42,43,44],"Diet","Secondary prevention","Coronary plaque regression","Atherosclerosis","Type 2 diabetes","Coronary heart disease","Myocardial infarction","Coronary computed tomography angiography","Healthy nordic diet","NAFLD","RECRUITING","2025-03-05",{"date":48,"type":49},"2025-03-06","ACTUAL",{"date":51,"type":22},"2025-03-20",{"date":53,"type":22},"2031-12-30",{"name":55,"class":56},"Uppsala University","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":67,"targetDuration":69,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100577160","progression-of-atheroma-evaluated-by-ct-angiography-and-intracoronary-imaging-techniques-100577160","NCT06794684","PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques","Evaluation of Atherosclerotic Plaque Progression by Coronary Computed Tomography Angiography and Intracoronary Imaging Techniques in Patients With Coronary Artery Disease","PRACTICE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinically significant angina pectoris, or suspected CAD\n* Receive coronary CTA scan, with a visible plaque (defined as ≥25% diameter stenosis) in major coronary arteries.\n\nExclusion Criteria:\n\n* Unsuitable for coronary CTA (such as severe renal impairment, uncontrolled thyroid condition, allergic to iodine, etc.)\n* Receive percutaneous coronary intervention (PCI) within 6 months\n* Prior history of myocardial infarction or heart failure\n* Prior history of percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)\n* Abnormal liver function (serum alanine aminotransferase \\[ALT\\] level exceeding 3 times the upper limit of normal) or abnormal kidney function (eGFR ≤30 ml\u002Fmin)\n* Familial hypercholesterolemia\n* Estimated survival ≤ 1 year\n* Malignant tumor\n* Pregnant or lactation, or have the intention to give birth within one year\n* Poor coordinance, unable to follow-up","18 Years",{"count":68,"type":22},50000,"2 Years","OBSERVATIONAL","This is a combined cohort study with retrospectively and prospectively enrolled coronary artery disease (CAD) patients. All the patients will undergo clinical follow-up for up to 5 years, and repeat coronary CTA will be conducted after 2 years. Comprehensive morphological and functional plaque analysis will be performed. The impact of these morphological and functional parameters, alongside cardiometabolic factors and pharmacological treatments on plaque progression and the occurrence of major adverse cardiovascular events (MACEs) will be analyzed. In addition, intracoronary imaging techniques will be used to improve the accuracy of plaque analysis by coronary CTA.",[73,29],"Coronary Arterial Disease (CAD)",[75,76,77,78,79,80],"Coronary CTA","Plaque Progression","coronary artery disease","high-risk plaques","plaque composition","intracoronary imaging","2025-01-21",{"date":83,"type":49},"2025-01-27",{"date":85,"type":49},"2016-01-01",{"date":87,"type":22},"2030-05-31",{"name":89,"class":56},"Ruijin Hospital",2,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":98,"targetDuration":100,"studyType":70,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":57},"100521900","complex-registry---a-prospective-cohort-study-to-describe-the-management-and-outcomes-of-patients-presenting-with-complex-and-calcified-coronary-artery-disease-100521900","NCT06075602","COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease","COMPLEX","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Individuals presenting with chronic, complex and\u002For calcified CAD and requiring PCI or CABG\n* Complex coronary artery disease \u002F lesions must include at least one of the following attributes:\n* Long and\u002F or heavily calcified coronary lesions\n* In-stent restenosis\n* Chronic total occlusions (CTO)\n* Left main lesions\n* Bifurcation lesions\n* Bypass graft lesions\n* Small vessel disease \u002F coronary microvascular dysfunction (e.g. not amenable to PCI)\n* Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).\n\nExclusion Criteria:\n\nThe presence of any one of the following exclusion criteria will lead to exclusion of the patient.\n\n* Patient is \\\u003C18 years of age\n* Patient unwilling or unable to provide informed consent\n* Patients with no complex and calcified CAD",{"count":99,"type":22},5000,"10 Years","The purpose of the COMPLEX Registry is to prospectively and retrospectively collect baseline, clinical and procedural data of patients who have undergone PCI or CABG for complex and\u002F or calcified chronic CAD, irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. The outcomes will be compared in different clinical subgroups (e.g. PCI vs. CABG). The impact of current PCI techniques\u002F devices, but also CABG strategies in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.",[28,103,104,29,105,106,107,108,109,110],"Coronary Artery Disease","Coronary Restenosis","Coronary Artery Calcification","Stable Chronic Angina","Angina Pectoris","Angina, Stable","Angina, Unstable","Stent Thrombosis","2024-10-27",{"date":113,"type":49},"2024-10-29",{"date":115,"type":49},"2021-11-01",{"date":117,"type":22},"2031-12-31",{"name":119,"class":56},"Luzerner Kantonsspital",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":127,"targetDuration":100,"studyType":70,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":57},"100438392","siroop-registry---a-prospective-registry-study-to-evaluate-the-outcomes-of-coronary-artery-disease-patients-treated-with-sirolimus-or-paclitaxel-eluting-balloon-catheters-100438392","NCT04988685","SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters","SIROOP","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Patients with significant acute or chronic coronary de-novo lesions or ISR lesions requiring treatment using PCI\n* Treatment with at least one DCB (device choice at the operator's discretion) In case of a patient with lesions treated at different procedural time, lesions will be separately collected and documented\n* Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).\n\nExclusion Criteria:\n\n* Patient is \\\u003C18 years of age\n* Patient unwilling or unable to provide informed consent\n* pregnancy and lactation\n* Indication for surgical revascularization",{"count":128,"type":22},2000,"The purpose of the SIROOP Registry is to retrospectively and prospectively collect baseline, clinical and procedural characteristics of patients who have undergone PCI and are treated with either currently available sirolimus or paclitaxel coated DCBs (see Table 1), irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. Outcomes will be compared in different clinical subgroups. The impact of current DCBs in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.",[28,103,104,29,105,106,107,108,109,110],{"date":113,"type":49},{"date":133,"type":49},"2021-06-01",{"date":117,"type":22},{"name":119,"class":56},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":143,"targetDuration":100,"studyType":70,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":57},"100426002","clinical-utility-and-outcome-prediction-of-cardiovascular-computed-tomography-predict-ct-100426002","NCT04827316","Clinical Utility and Outcome Prediction of Cardiovascular Computed Tomography (PREDICT-CT)","PREDICT-CT","Inclusion Criteria:\n\n* Adult individual \\>18 years\n* Undergoing clinically indicated CCTA\n* Signed informed consent or waiver\n\nExclusion Criteria:\n\n* None",{"count":144,"type":22},4200,"In this study the investigators retrospectively and prospectively collect information from enrolled subjects undergoing CCTA and evaluate the association of cardiac and non-cardiac imaging with laboratory markers and clinical data including outcome.",[103,29,147],"Coronary; Ischemic",[149],"Cardiovascular Computed Tomography","2024-10-16",{"date":152,"type":49},"2024-10-18",{"date":154,"type":49},"2017-06-01",{"date":156,"type":22},"2031-02-01",{"name":158,"class":56},"Insel Gruppe AG, University Hospital Bern"]